The SMaRT plant (Sumitomo Dainippon Manufacturing Plant for Regenerative Medicine & Cell Therapy is claimed to be the world’s first commercial facility dedicated to regenerative and cellular medicine derived from iPS cells and has 2 floors above ground and a total floor area of 2,915 m2. At present, the focus is on age-related macular degeneration, Parkinson’s disease, retinal pigment degeneration, spinal cord injury etc, and will conduct investigational drug manufacturing and early commercial production
Dainippon Sumitomo news release, March 1, 2018
Dainippon Somuitomo opens manufacturing plant for regenerative medicine in Osaka